Deferasirox

• CAT Number: A000774
• CAS Number: 201530-41-8
• Molecular Formula: C21H15N3O4
• Molecular Weight: 373.40
• Purity: ≥95%
• Synonyms: Deferasiroxum; 201530-41-8; ICL 670; Exjade; ICL 670A
• Target: Cyclin-Dependent Kinases
• Solubility: >11.9mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid
• InChI: InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)
• InChIKey: BOFQWVMAQOTZIW-UHFFFAOYSA-N
• SMILES: C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O

Deferasirox（Cat No.:A000774）is an oral iron chelator used to treat chronic iron overload, particularly in patients requiring regular blood transfusions, such as those with thalassemia or sickle cell anemia. It binds to excess iron in the bloodstream, forming complexes that are then excreted via feces, helping to prevent iron accumulation and its toxic effects on organs. Known for its once-daily dosing and effectiveness, Deferasirox is preferred for long-term management of iron overload, reducing risks of heart, liver, and endocrine complications. Its convenience and efficacy make it a valuable option in iron chelation therapy.

Reference

1: Allegra S, Cusato J, De Francia S, Arduino A, Longo F, Pirro E, Massano D, De
Nicolò A, Piga A, D/’Avolio A. Role of CYP24A1, VDR and GC gene polymorphisms on
deferasirox pharmacokinetics and clinical outcomes. Pharmacogenomics J. 2017 Nov
21. doi: 10.1038/tpj.2017.43. [Epub ahead of print] PubMed PMID: 29160302.

2: Yesilipek MA, Karasu G, Kaya Z, Kuskonmaz BB, Uygun V, Dag I, Ozudogru O,
Ertem M. A Phase II, Multicenter, Single-Arm Study to Evaluate the Safety and
Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation in Children
with Β-Thalassemia Major. Biol Blood Marrow Transplant. 2017 Nov 16. pii:
S1083-8791(17)30820-0. doi: 10.1016/j.bbmt.2017.11.006. [Epub ahead of print]
PubMed PMID: 29155313.

3: Allegra S, Cusato J, De Francia S, Longo F, Pirro E, Massano D, Piga A,
D/’Avolio A. Effect of pharmacogenetic markers of vitamin D pathway on deferasirox
pharmacokinetics in children. Pharmacogenet Genomics. 2017 Nov 2. doi:
10.1097/FPC.0000000000000315. [Epub ahead of print] PubMed PMID: 29099735.

4: Lescano MA, Tavares LC, Santos PCJL. Juvenile hemochromatosis: HAMP mutation
and severe iron overload treated with phlebotomies and deferasirox. World J Clin
Cases. 2017 Oct 16;5(10):381-383. doi: 10.12998/wjcc.v5.i10.381. PubMed PMID:
29085829; PubMed Central PMCID: PMC5649000.

5: Salehi S, Saljooghi AS, Badiee S, Moqadam MM. Chelation of Thallium (III) in
Rats Using Combined Deferasirox and Deferiprone Therapy. Toxicol Res. 2017
Oct;33(4):299-304. doi: 10.5487/TR.2017.33.4.299. Epub 2015 Oct 15. PubMed PMID:
29071014; PubMed Central PMCID: PMC5654193.

6: Shen JC, Zhang YC, Zhao MF. Protective effects of deferasirox and
N-acetyl-L-cysteine on iron overload-injured bone marrow. Braz J Med Biol Res.
2017 Oct 19;50(12):e6087. doi: 10.1590/1414-431X20176087. PubMed PMID: 29069221;
PubMed Central PMCID: PMC5649863.

7: Osborne V, Davies M, Layton D, Shakir SAW. Utilisation and Safety of
Deferasirox: Results from an Observational Cohort Study in England. Drug Saf.
2017 Oct 10. doi: 10.1007/s40264-017-0606-2. [Epub ahead of print] PubMed PMID:
29019038.

8: Maximova N, Gregori M, Simeone R, Sonzogni A, Boz G, Fucile C, Marini V,
Martelli A, Mattioli F. Safety and tolerability of deferasirox in pediatric
hematopoietic stem cell transplant recipients: one facility/’s five years/’
experience of chelation treatment. Oncotarget. 2017 Jun 28;8(38):63177-63186.
doi: 10.18632/oncotarget.18725. eCollection 2017 Sep 8. PubMed PMID: 28968980;
PubMed Central PMCID: PMC5609912.

9: Ansari S, Azarkeivan A, Miri-Aliabad G, Yousefian S, Rostami T. Comparison of
iron chelation effects of deferoxamine, deferasirox, and combination of
deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior.
Caspian J Intern Med. 2017 Summer;8(3):159-164. doi: 10.22088/cjim.8.3.159.
PubMed PMID: 28932366; PubMed Central PMCID: PMC5596185.

10: Thakor DR, Desai CK, Kapadia JD, Dikshit RK, Mehariya KM. Efficacy and Safety
of Deferasirox in Pediatric Patients of Thalassemia at a Tertiary Care Teaching
Hospital. Indian J Med Paediatr Oncol. 2017 Apr-Jun;38(2):103-110. doi:
10.4103/ijmpo.ijmpo_103_16. PubMed PMID: 28900315; PubMed Central PMCID:
PMC5582544.